RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Kathleen Sullivan to Pyrimidines

Back to Details
This is a "connection" page, showing publications Kathleen Sullivan has written about Pyrimidines.
Kathleen Sullivan
Connection Strength
0.091
Pyrimidines
  1. Rudra S, Shaul E, Conrad M, Patel T, Moore A, Dawany N, Canavan MC, Sullivan KE, Behrens E, Kelsen JR. Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 06; 20(6):1408-1410.e2.
    View in: PubMed
    Score: 0.046
  2. Triebwasser MP, Barrett DM, Bassiri H, Bunin N, Elgarten C, Freedman J, Geera AS, Monos D, Lambert MP, Olson T, Seif AE, Paessler M, Petrosa W, Reilly AF, Romberg N, Sullivan KE, Quinn GZ, Behrens E, Teachey DT. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatr Blood Cancer. 2021 07; 68(7):e29026.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support